– In countries where it is legal for Tasigna for the treatment of chronic phase and accelerated phase Philadelphia chromosome – positive chronic myeloid leukemia in adult patients resistant or intolerant to at least one prior therapy with Glivec appear. The effectiveness of Tasigna is shown on hematological and cytogenetic There are no controlled trials. Clinical benefit, such as improvement in disease-related symptoms or increased survival.
New data from a small clinical trial compared with Gleevec in the treatment of newly diagnosed patients with chronic phase CML were presented at the ASH Annual Meeting. All evaluable patients achieved a complete cytogenetic response within six months of treatment with Tasigna . After 12 months was major molecular response in 45 percent of patients achieved Tasigna. The most frequent adverse events were thrombocytopenia, neutropenia and anaemia3.HPV vaccine immunization rates raising in the U.S.continuation increase – so much as 15 % – were widely available, specially designed for vaccines recommended for pre-teens, after 2009 after 2009 National Immunization Survey – Teenager , published through the Centres for Disease Disease Control and Prevention.